摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-benzilossi-1,2,3,4-tetraidrochinolina | 75893-80-0

中文名称
——
中文别名
——
英文名称
6-benzilossi-1,2,3,4-tetraidrochinolina
英文别名
6-(Benzyloxy)-1,2,3,4-tetrahydroquinoline;6-phenylmethoxy-1,2,3,4-tetrahydroquinoline
6-benzilossi-1,2,3,4-tetraidrochinolina化学式
CAS
75893-80-0
化学式
C16H17NO
mdl
——
分子量
239.317
InChiKey
IIBAIGFSRDHPLM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    18
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    21.3
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933499090

反应信息

  • 作为反应物:
    描述:
    6-benzilossi-1,2,3,4-tetraidrochinolina 在 monoamine oxidase 作用下, 以 aq. phosphate buffer 、 二甲基亚砜 为溶剂, 以50%的产率得到6-(苄氧基)喹啉
    参考文献:
    名称:
    单胺氧化酶 (MAO-N) 和辣根过氧化物酶 (HRP) 生物催化剂生物催化和化学酶法合成喹啉和 2-喹诺酮
    摘要:
    脂肪族N-杂环的氧化芳构化是制备多种杂芳族化合物的基本有机转化。尽管许多人尝试提高这种转化的效率和实用性,但大多数合成方法仍然需要有毒且昂贵的试剂以及恶劣的条件。在此,我们描述了将 1,2,3,4-四氢喹啉 (THQ) 和N-环丙基-N-烷基苯胺分别氧化成喹啉和 2-喹诺酮的两种酶促策略。利用全细胞和纯化的单胺氧化酶(MAO-N)有效催化THQ生物转化为相应的芳香族喹啉衍生物,而N-环丙基-N-烷基苯胺则通过辣根过氧化物酶(HRP)转化为2-喹诺酮化合物。 -催化环化/芳构化反应,然后进行铁介导的氧化。
    DOI:
    10.1021/acscatal.2c05902
  • 作为产物:
    描述:
    溴甲苯吡啶硼烷potassium carbonate 作用下, 以 溶剂黄146丙酮 为溶剂, 反应 72.0h, 生成 6-benzilossi-1,2,3,4-tetraidrochinolina
    参考文献:
    名称:
    Ferranti; Garuti; Giovanninetti, Farmaco, Edizione Scientifica, 1987, vol. 42, # 4, p. 237 - 249
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Novel heterocyclic derivatives
    申请人:——
    公开号:US20040157850A1
    公开(公告)日:2004-08-12
    The object of the present invention is to provide soluble &bgr;-amyloid precursor protein secretory stimulators, which are effective in treating neurodegenerative diseases as well as cerebrovascular disorder-induced neuronopathy. More specifically, the present invention provides a novel compound of the following Formula (I) or a salt or prodrug thereof: 1 [wherein R 1 and R 2 each represent a hydrogen atom or a lower alkyl group, etc., Ar 1 and the ring B each represent an optionally substituted aromatic group, the ring A represents an optionally substituted benzene ring, the ring C represents an optionally substituted 4- to 8-membered ring which may further be condensed with an optionally substituted ring, X represents CH or N, and Y represents CH or N].
    本发明的目的是提供可溶性β-淀粉样前体蛋白分泌刺激剂,其对治疗神经退行性疾病以及脑血管疾病引起的神经病变具有有效性。更具体地说,本发明提供了以下式(I)的新化合物或其盐或前药:1 [其中,R1和R2分别代表氢原子或较低的烷基等,Ar1和环B分别代表可选取代的芳香族基团,环A代表可选取代的苯环,环C代表可选取代的4-至8-成员环,可以进一步与可选取代的环融合,X代表CH或N,Y代表CH或N]。
  • 6,7-DIHYDROIMIDAZO [2,1-b] [1,3]OXAZINE BACTERICIDES
    申请人:Kawano Yoshikazu
    公开号:US20140031342A1
    公开(公告)日:2014-01-30
    The present invention provides a novel 6,7-dihydroimidazo[2,1-b][1,3]oxazine compound that has excellent bactericidal action against tubercle bacilli, multidrug-resistant tubercle bacilli, and atypical acid-fast bacilli. Specifically, the present invention provides a compound represented by Formula (1): or a salt thereof, wherein R 1 represents tetrahydroisoquinolyl, tetrahydroquinolyl, tetrahydrobenzoazepinyl, benzoxazolyl, benzothiazolyl, indolyl, isoindolinyl, naphthyl, quinolyl, phenyl, biphenylyl, or pyridyl, these groups being optionally substituted, the phenyl, biphenylyl, and pyridyl represented by R 1 each being substituted directly or via a linker with at least one group selected from the group consisting of tetrahydropyridyl, diazepanyl, diazabicycloheptanyl, tetrahydrotriazolopyrazinyl, tetrahydroimidazopyrazinyl, azabicyclooctanyl, oxazolyl, piperazinyl, piperidyl, thiazolyl, and the like, each of these groups being optionally substituted; and R 2 represents hydrogen or lower alkyl. The present invention further provides a pharmaceutical composition containing the above.
    本发明提供了一种新型的6,7-二氢咪唑[2,1-b][1,3]噁嗪化合物,该化合物对结核杆菌、多重耐药结核杆菌和非典型酸杆菌具有优异的杀菌作用。具体而言,本发明提供了一个由式(1)表示的化合物或其盐,其中R1表示四氢异喹啉基、四氢喹啉基、四氢苯并氮杂环庚基、苯并噁唑基、苯并噻唑基、吲哚基、异吲哚啉基、基、喹啉基、苯基、联苯基或吡啶基,这些基团可以被替代,其中R1所表示的苯基、联苯基和吡啶基可以通过连接基直接或经过连接基与选自四氢吡啶基、二氮杂环庚基、二氮杂双环庚基、四氢三唑吡嗪基、四氢咪唑吡嗪基、氮杂双环辛基、噁唑基、哌嗪基、哌啶基噻唑基等基团中的至少一个基团取代,其中这些基团可以被替代;而R2表示氢或低碳基。本发明还提供了一种包含上述化合物的药物组合物。
  • 6,7-dihydroimidazo [2,1-b] [1,3]oxazine bactericides
    申请人:Kawano Yoshikazu
    公开号:US09051333B2
    公开(公告)日:2015-06-09
    The present invention provides a novel 6,7-dihydroimidazo[2,1-b][1,3]oxazine compound that has excellent bactericidal action against tubercle bacilli, multidrug-resistant tubercle bacilli, and atypical acid-fast bacilli. Specifically, the present invention provides a compound represented by Formula (1): or a salt thereof, wherein R1 represents tetrahydroisoquinolyl, tetrahydroquinolyl, tetrahydrobenzoazepinyl, benzoxazolyl, benzothiazolyl, indolyl, isoindolinyl, naphthyl, quinolyl, phenyl, biphenylyl, or pyridyl, these groups being optionally substituted, the phenyl, biphenylyl, and pyridyl represented by R1 each being substituted directly or via a linker with at least one group selected from the group consisting of tetrahydropyridyl, diazepanyl, diazabicycloheptanyl, tetrahydrotriazolopyrazinyl, tetrahydroimidazopyrazinyl, azabicyclooctanyl, oxazolyl, piperazinyl, piperidyl, thiazolyl, and the like, each of these groups being optionally substituted; and R2 represents hydrogen or lower alkyl. The present invention further provides a pharmaceutical composition containing the above.
    本发明提供了一种新型的6,7-二氢咪唑[2,1-b][1,3]噁嗪化合物,具有对结核分枝杆菌、多重耐药结核分枝杆菌和非典型酸性革兰氏阳性杆菌的优异杀菌作用。具体而言,本发明提供了下式(1)表示的化合物或其盐,其中R1表示四氢异喹啉基、四氢喹啉基、四氢苯并氮杂环庚基、苯并噁唑基、苯并噻唑基、吲哚基、异吲哚啉基、基、喹啉基、苯基、联苯基或吡啶基,这些基团可以选择性地被取代,其中由R1表示的苯基、联苯基和吡啶基可以通过连接基直接或经过至少选择自四氢吡啶基、二氮杂环庚基、二氮杂双环庚基、四氢三唑吡嗪基、四氢咪唑吡嗪基、氮杂双环辛基、噁唑基、哌嗪基、哌啶基噻唑基等基团中至少一个取代基进行取代;R2表示氢或低碳基。本发明还提供了包含上述化合物的药物组合物。
  • NOVEL HETEROCYCLIC DERIVATIVES
    申请人:Takeda Chemical Industries, Ltd.
    公开号:EP1382598A1
    公开(公告)日:2004-01-21
    The object of the present invention is to provide soluble β-amyloid precursor protein secretory stimulators, which are effective in treating neurodegenerative diseases as well as cerebrovascular disorder-induced neuronopathy. More specifically, the present invention provides a novel compound of the following Formula (I) or a salt or prodrug thereof: [wherein R1 and R2 each represent a hydrogen atom or a lower alkyl group, etc., Ar1 and the ring B each represent an optionally substituted aromatic group, the ring A represents an optionally substituted benzene ring, the ring C represents an optionally substituted 4- to 8-membered ring which may further be condensed with an optionally substituted ring, X represents CH or N, and Y represents CH or N].
    本发明的目的是提供可溶性β-淀粉样前体蛋白分泌刺激剂,它能有效治疗神经退行性疾病以及脑血管疾病引起的神经元病变。更具体地说,本发明提供了下式(I)的新型化合物或其盐或原药: [其中 R1 和 R2 分别代表氢原子或低级烷基等,Ar1 和环 B 分别代表任选取代的芳香基团,环 A 代表任选取代的苯环,环 C 代表任选取代的 4 至 8 元环,可进一步缩合任选取代的环,X 代表 CH 或 N,Y 代表 CH 或 N]。
  • 6,7-DIHYDROIMIDAZO[2,1-B][1,3]OXAZINE BACTERICIDES
    申请人:OTSUKA PHARMACEUTICAL CO., LTD.
    公开号:EP2697232B1
    公开(公告)日:2016-05-18
查看更多